Advanced in Ewing Sarcoma
Advanced in Ewing Sarcoma
2501 N Orange Ave, Suite 589, 
Orlando, FL 

Overview

Fouad Hajjar is a Pediatric Hematologist Oncology provider in Orlando, Florida. Dr. Hajjar is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Hepatoblastoma, Reticulohistiocytoma, Histiocytosis, Langerhans Cell Histiocytosis, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 10 peer reviewed articles and participating in 52 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 11 clinical trials in the study of Ewing Sarcoma.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 8 Less Insurance Carriers -

Locations

2501 N Orange Ave, Suite 589, Orlando, FL 32804

Additional Areas of Focus

Dr. Hajjar has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


52 Clinical Trials

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age
View 49 Less Clinical Trials
Similar Doctors
Advanced in Ewing Sarcoma
Pediatric Hematology Oncology
Advanced in Ewing Sarcoma
Pediatric Hematology Oncology
6535 Nemours Pkwy, 
Orlando, FL 
 (14.9 miles away)
Languages Spoken:
English

Erlyn Smith is a Pediatric Hematologist Oncology provider in Orlando, Florida. Dr. Smith is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Aspiration.

Experienced in Ewing Sarcoma
Pediatric Hematology Oncology
Experienced in Ewing Sarcoma
Pediatric Hematology Oncology
92 W Miller St, 
Orlando, FL 
 (3.6 miles away)
Languages Spoken:
English

Vincent Giusti is a Pediatric Hematologist Oncology provider in Orlando, Florida. Dr. Giusti is rated as an Experienced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Langerhans Cell Histiocytosis, Intersex, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Aspiration.

Experienced in Ewing Sarcoma
Pediatric Hematology Oncology | Hematology | Pediatrics
Experienced in Ewing Sarcoma
Pediatric Hematology Oncology | Hematology | Pediatrics
92 W Miller St, 
Orlando, FL 
 (3.6 miles away)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Mark Mogul is a Pediatric Hematologist Oncology specialist and a Hematologist in Orlando, Florida. Dr. Mogul is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Ependymoma, Langerhans Cell Histiocytosis, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Aspiration. Dr. Mogul is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hajjar's expertise for a condition
ConditionClose
      View All 15 Advanced Conditions
      View All 7 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile